Engineering probiotic Escherichia coli Nissle 1917 to block transfer of multiple antibiotic resistance genes by exploiting a type I CRISPR-Cas system.
Mengdie FangRuiting ZhangChenyu WangZhizhi LiuMingyue FeiBiao TangHua YangDongchang SunPublished in: Applied and environmental microbiology (2024)
Nissle 1917 (EcN), which has been used for treating intestinal diseases and developed as living therapeutics. We also demonstrate that the type I CRISPR-Cas system imposes a lower growth burden than the type II CRISPR-Cas system, highlighting its promising clinical application potential. Our work not only provides a new strategy for restricting the transfer of ARGs while using probiotics but also enriches the genetic engineering toolbox of EcN, paving the way for the safe use and development of probiotics as living therapeutics.
Keyphrases
- crispr cas
- antibiotic resistance genes
- genome editing
- escherichia coli
- wastewater treatment
- microbial community
- small molecule
- anaerobic digestion
- genome wide
- copy number
- gene expression
- pseudomonas aeruginosa
- climate change
- electron transfer
- dna methylation
- cystic fibrosis
- staphylococcus aureus
- lactic acid
- multidrug resistant